MXPA05013898A - Mejoramiento de la actividad y/o duracion de la accion de esteroides antiinflamatorios suaves para la aplicacion topica u otra aplicacion local. - Google Patents

Mejoramiento de la actividad y/o duracion de la accion de esteroides antiinflamatorios suaves para la aplicacion topica u otra aplicacion local.

Info

Publication number
MXPA05013898A
MXPA05013898A MXPA05013898A MXPA05013898A MXPA05013898A MX PA05013898 A MXPA05013898 A MX PA05013898A MX PA05013898 A MXPA05013898 A MX PA05013898A MX PA05013898 A MXPA05013898 A MX PA05013898A MX PA05013898 A MXPA05013898 A MX PA05013898A
Authority
MX
Mexico
Prior art keywords
duration
activity
action
alkyl
topical
Prior art date
Application number
MXPA05013898A
Other languages
English (en)
Spanish (es)
Inventor
Nicholas S Bodor
Original Assignee
Nicholas S Bodor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas S Bodor filed Critical Nicholas S Bodor
Publication of MXPA05013898A publication Critical patent/MXPA05013898A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
MXPA05013898A 2003-06-19 2004-06-17 Mejoramiento de la actividad y/o duracion de la accion de esteroides antiinflamatorios suaves para la aplicacion topica u otra aplicacion local. MXPA05013898A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47949603P 2003-06-19 2003-06-19
PCT/US2004/019367 WO2005000317A1 (en) 2003-06-19 2004-06-17 Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application

Publications (1)

Publication Number Publication Date
MXPA05013898A true MXPA05013898A (es) 2006-05-25

Family

ID=33551891

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013898A MXPA05013898A (es) 2003-06-19 2004-06-17 Mejoramiento de la actividad y/o duracion de la accion de esteroides antiinflamatorios suaves para la aplicacion topica u otra aplicacion local.

Country Status (12)

Country Link
US (2) US7560448B2 (ja)
EP (1) EP1653974B1 (ja)
JP (1) JP4893305B2 (ja)
KR (1) KR20060032596A (ja)
CN (1) CN1838960A (ja)
AT (1) ATE454154T1 (ja)
CA (1) CA2558944C (ja)
DE (1) DE602004025002D1 (ja)
ES (1) ES2339351T3 (ja)
HK (1) HK1089690A1 (ja)
MX (1) MXPA05013898A (ja)
WO (1) WO2005000317A1 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
JP5257073B2 (ja) * 2005-11-10 2013-08-07 ボーダー、ニコラス・エス ソフト型抗コリン作動性エステル
WO2007058935A2 (en) * 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
GB0523251D0 (en) * 2005-11-15 2005-12-21 Glaxo Group Ltd Novel compounds
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
MX2009009213A (es) * 2007-03-01 2010-03-15 Univ America Catholic Bacteriofago t4 unido a un substrato.
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
KR20170005191A (ko) * 2009-01-06 2017-01-11 큐어론 엘엘씨 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
GB2480772B (en) 2009-01-06 2013-10-16 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
MX347770B (es) 2011-04-21 2017-05-12 Curemark Llc Compuesto para el tratamiento de alteraciones neuropsiquiatricas.
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2022225999A1 (en) * 2021-04-19 2022-10-27 Bodor Laboratories, Inc. Lung-targeted corticosteroid treatment in viral respiratory disease, covid-19 and ards (acute respiratory distress syndrome)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1384372A (en) 1971-01-20 1975-02-19 Glaxo Lab Ltd Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
US3828080A (en) 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
CH628355A5 (de) 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4996335A (en) * 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
ZA814440B (en) * 1980-07-10 1982-10-27 Otsuka Pharma Co Ltd Soft steroids having anti-inflammatory activity
US4496335A (en) * 1982-12-13 1985-01-29 Dayco Corporation Pulley construction and method of making the same
US5981517A (en) 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
TW503113B (en) * 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
US20020028193A1 (en) 2000-02-15 2002-03-07 Cornett Lawrence E. Recombinant beta2-adrenergic receptor delivery and use in treating airway and vascular diseases

Also Published As

Publication number Publication date
DE602004025002D1 (de) 2010-02-25
JP4893305B2 (ja) 2012-03-07
US7923441B2 (en) 2011-04-12
JP2007520437A (ja) 2007-07-26
HK1089690A1 (en) 2006-12-08
EP1653974A1 (en) 2006-05-10
CA2558944C (en) 2012-05-29
US20050026892A1 (en) 2005-02-03
CA2558944A1 (en) 2005-01-06
US20090239833A1 (en) 2009-09-24
ES2339351T3 (es) 2010-05-19
ATE454154T1 (de) 2010-01-15
WO2005000317A1 (en) 2005-01-06
EP1653974B1 (en) 2010-01-06
CN1838960A (zh) 2006-09-27
KR20060032596A (ko) 2006-04-17
US7560448B2 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
MXPA05013898A (es) Mejoramiento de la actividad y/o duracion de la accion de esteroides antiinflamatorios suaves para la aplicacion topica u otra aplicacion local.
TW200603813A (en) Cyclic progestin regimens and kits
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
EA200201000A1 (ru) Гормон-заместительная терапия
TW200605880A (en) Progesterone receptor antagonist contraceptive regimens and kits
DK0748190T3 (da) Progestogenfrie formuleringer af GnRH og estrogen til behandling af benigne gynækologiske lidelser
HK1089691A1 (en) Enhancement of activity and/or duration of action of selected anti-inflammatory steroids
CA2152425A1 (en) Rubber composition comprising highly saturated nitrile rubber and ethylenically saturated copolymer rubber
NZ524104A (en) Exemestane as chemopreventing agent
PL374317A1 (en) Composition containing an androgenous 11beta-halogen steroid and a progestational hormone, and male contraceptive based on said composition
ATE292133T1 (de) Kaliumkanäleöffner
IL164159A0 (en) C-17 spirolactonization and 6,7 oxidation of steroids
DE60016181D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
WO2007142842A3 (en) Combination of anti-inflammatory steroids having transporter-enhanced corticosteroid activity
EP1249239A4 (en) ANTI-PRIMARY AGENT FOR EXTERNAL USE
WO2003104254A3 (en) NOVEL ANDROSTANE AND ANDROSTENE DERIVATIVES WITH ASCORBIC ACID AND THEIR USE IN THE TREATMENT OR PREVENTION OF DIFFERENT CONDITIONS, DISEASES AND DISORDERS
DE602004018921D1 (de) D dienogest
BR0311184A (pt) Terapia de reposição de hormÈnio
GB1164554A (en) Process and Intermediates for manufacture of 17-Oxygenated Estra-4-en-3-ones
DE60002692D1 (de) Leberspezifische gallensaeurederivate des antiglukokorticoids ru486
DE60014096D1 (de) Durch 11-beta-aryl-17,17-spirothiolan substituierte steroide
HK1063473A1 (en) Stabilized derivatives of ascorbic acid-3-phosphate
EP1808176A3 (en) 5 alpha reduced glucocorticoid metabolites for the treatment of inflammation
WO2004093852A3 (en) Use of steroid derivatives for the treatment of angiotensin ii related disease e.g. cardiovascular and proliferative disorders

Legal Events

Date Code Title Description
FG Grant or registration